Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore
- 9 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 149 (2), 263-272
- https://doi.org/10.1007/s11060-020-03594-6
Abstract
Purpose Monitoring neurological side-effects in experimental therapy for diffuse intrinsic pontine glioma (DIPG) can be challenging. We aimed to develop a neurological scale that could be used by non-specialists to quantify neurological changes during experimental treatment of DIPG. Methods We developed the Pontine Observational Neurological Score (PONScore) to measure signs and symptoms of DIPG by adapting validated assessment scales of neurological signs and symptoms in children. We developed a prototype score, taught it to paediatric intensive care nursing staff, who used the Score to assess children receiving awake pontine infusion of chemotherapy for treatment of DIPG. We used their feedback to develop the PONScore. Points are allocated for headache, ophthalmoplegia, facial and tongue weakness, dysarthria, paraesthesia, limb weakness and dysmetria with increasing scores reflecting increasing disability. The PONScore was administered every hour during awake pontine infusion. Correlation and agreement calculations between nursing staff, as non-specialists, and a specialist rater were performed in 30 infusions in 6 children (aged 8–11). Changes in PONScore versus volume of infusion are described in a further 55 infusions in 8 children (aged 3–11). Results The PONScore demonstrated excellent intra-rater reliability with an intra-class co-efficient of 0.98 (95% CI 0.97–0.99; p-value < 0.001) between a specialist and non-specialist raters with strong correlation between scores and a Spearman correlation coefficient of 0.985 (p < 0.001). PONScores increased from 3.3 to 5.7 (p-value < 0.001) during infusion reflecting accumulation of neurological signs and symptoms during infusion. Conclusions We describe a novel neurological scale that can be used by non-specialists to describe acute neurological changes in children receiving experimental therapy for DIPG. Prospective validation as part of a clinical trial is required.Keywords
This publication has 26 references indexed in Scilit:
- HIGHLY SELECTIVE INTRA-ARTERIAL CHEMOTHERAPY FOR THE TREATMENT OF PROGRESSIVE DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)Neuro-Oncology, 2014
- Development of a New Lingual Range-of-Motion Assessment Scale: Normative Data in Surgically Treated Oral Cancer PatientsDysphagia, 2014
- A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastomaDrug Delivery, 2014
- Ataxia rating scales are age‐dependent in healthy childrenDevelopmental Medicine and Child Neurology, 2014
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010Neuro-Oncology, 2013
- Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem gliomaActa Neurochirurgica, 2013
- Interrater Reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a Multicenter StudyStroke, 2011
- Scale for the assessment and rating of ataxiaNeurology, 2006
- Diffuse brainstem glioma in children: critical review of clinical trialsThe Lancet Oncology, 2006
- Convection-enhanced delivery of macromolecules in the brain.Proceedings of the National Academy of Sciences of the United States of America, 1994